Ulcerative Colitis

In the first study, researchers from England treated more than 200 IBD patients with one of a number of NSAIDs for four weeks.

The patients were monitored every four to 12 months for a relapse in their condition.

In the end, researchers say patients with IBD are able to tolerate short-term use of NSAIDs and less than one in three is likely to experience a flare-up in symptoms.

They also discovered COX-2 inhibitors, previously believed to symptom recurrence, reduced the likelihood of a relapse.

Based on these findings, researchers say, "The tolerability to the selective COX- inhibitor nimesulide and low-dose aspirin might be important when contemplating anti-inflammatory analgesic and cardiovascular prophylactic treatment, respectively, in these patients." The second study, out of the Mayo Clinic in Rochester, Minn., examined the effect of COX-2 inhibitors on more than 200 Patients were treated with either celecoxib (Celebrex) or a placebo for two weeks.

They were observed for disease exacerbation.

The study showed no significant relapse in patients on the active medication compared to those on the placebo.

Researchers say these findings warrant further studies to determine whether celecoxib could be a safe treatment for colitis patients.

This article was reported by Ivanhoe.com, who offers Medical Alerts by ...

The securities issued in the private placement have not been registered under the Securities Act of 1933, as amended.

Accordingly, these securities may not be offered or sold in the United States, except pursuant to the effectiveness of a registration statement or an applicable exemption from the registration requirements of the Securities Act.

Callisto has agreed to file a registration statement covering resale of the securities by the private placement investors.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities.

About Callisto Pharmaceuticals, Inc.

Callisto is a biopharmaceutical company focused on the development of new drugs to treat various forms of cancer and other serious afflictions.

Callisto's drug candidates in development currently include anti-cancer agents in clinical development, in addition to drugs for a range of other significant health care market segments, including biodefense.

One of the Company's lead drug candidates, L-Annamycin, is being developed as a treatment for forms of relapsed leukemia, a currently incurable blood cancer.

Callisto initiated a clinical trial of L-Annamycin in adult relapsed acute lymphocytic leukemia patients in 4Q 2005.

L-Annamycin, a new compound from the anthracycline family of prov...

IBD can cause serious complications, including colon cancer in people with long-term disease.

About the Mankoff Family Foundation The Mankoff Family Foundation was founded in 1997 by Ronald M.

and Joy S.

Mankoff.

The Foundation provides financial support to a variety of local and national organizations.

In addition to Ronald and Joy Mankoff, other members of the Mankoff family serve as directors of the Foundation including Douglas Mankoff, Jeffrey Mankoff, Marcia Mankoff and Staci Mankoff.

About CCFA The Crohn's & Colitis Foundation of America's (CCFA) mission is to cure and prevent Crohn's disease and Every year, at least 80 cents of every dollar the foundation spends goes to mission-critical programs.

CCFA consistently meets the standards of organizations that monitor charities, including the Better Business Bureau (give.org) and the American Institute of Philanthropy (charitywatch.org).

For more information, contact CCFA at 800-932-2423 or visit www.ccfa.org.

Subscribe to the paper for less than thirty cents a day!

Copyright Notice & Privacy Policy Report a Proble...